Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8871737 Substituted nucleotide analogs

Patent 8871737 was granted and assigned to Alios BioPharma, Inc. on October, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Current Assignee

Alios BioPharma, Inc.

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Natalia Dyatkina0

David Bernard Smith0

Guangyi Wang0

Jerome Deval0

Leonid Beigelman0

Date of Patent

October 28, 2014

Patent Application Number

13236435

Date Filed

September 19, 2011

Patent Citations Received

US Patent 12084473 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

0

US Patent 12012431 Methods of preparing 1′-cyano nucleosides

0

US Patent 11701372 Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs

0

US Patent 11707480 Highly active compounds against COVID-19

0

US Patent 12006340 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

0

US Patent 11780844 Compounds and methods for treatment of viral infections

US Patent 11786544 Formulations of phosphoramidate derivatives of nucleoside drugs

US Patent 11851438 1′-cyano nucleoside analogs and methods for treatment of viral infections

0

...

Patent Primary Examiner

Lawrence E Crane

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8871737 Substituted nucleotide analogs

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.